{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:32:27Z","timestamp":1790191947138,"version":"4.1.0"},"reference-count":15,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background: Treatment of Philadelphia chromosome negative myeloproliferative neoplasms (Ph \u2013 MPNs)<\/jats:bold>\n                    requires individualized approach depending on multiple factors. Novel pegylated Interferon (IFN) formulations have become an attractive therapeutic option in young Ph- MPN patients associated with better patient compliance.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    : In this retrospective observational study a total of 16 high-risk Ph- MPN patients treated off-label with ropeginterferon alfa-2b given twice monthly, were included. Median follow-up was 24 months. High-risk patients were defined using the IPSET score. Response to treatment was evaluated using ELN, IWG-MET EUMNET standardized criteria and occurrence of side effects was documented.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : 11 patients were female (68.8%) and 5 male (31.2%); average age at diagnosis was 36 years (17-51); 12 patients (75%) had ET, one (6.2%) PV and three (18.8%) hypercellular phase of PMF. JAK2V617F mutation was detected in 10 patients (62.5%), CALR in three (18.8%), and three (18.7%) were triple-negative cases. In 7 patients (43.7%), ropeginterferon alfa-2b was used in first-line, and 9 (56.3%) were previously treated with HU and\/or standard IFN. Among initially ropeginterferon alfa-2b treated patients, complete haematological response was observed in 4\/7 (57.1%), partial in 2\/7 (28.6%) and suboptimal in one (14.3%). Complete haematological response was observed in 8\/9 (88.9%) among previously treated patients. Average time to blood count normalization was 8 weeks, at a dose ranging between 100mcg and 300mcg. Side effects were observed in one patient (6.2%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    : Our experience is in support of previous studies regarding ropeginterferon alfa-2b efficacy and safety profile in the treatment of young patients with Ph- MPNs.\n                  <\/jats:p>","DOI":"10.2478\/prilozi-2023-0047","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T14:48:22Z","timestamp":1702910902000},"page":"57-62","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms\u2013 Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience"],"prefix":"10.2478","volume":"44","author":[{"given":"Marija","family":"Popova-Labachevska","sequence":"first","affiliation":[{"name":"University clinic of hematology, Faculty of Medicine , Ss. Cyril and Methodius University in Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milche","family":"Cvetanoski","sequence":"additional","affiliation":[{"name":"University clinic of hematology, Faculty of Medicine , Ss. Cyril and Methodius University in Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevenka","family":"Ridova","sequence":"additional","affiliation":[{"name":"University clinic of hematology, Faculty of Medicine , Ss. Cyril and Methodius University in Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Trajkova","sequence":"additional","affiliation":[{"name":"University clinic of hematology, Faculty of Medicine , Ss. Cyril and Methodius University in Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Stojanovska-Jakimovska","sequence":"additional","affiliation":[{"name":"University clinic of hematology, Faculty of Medicine , Ss. Cyril and Methodius University in Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Mojsovska","sequence":"additional","affiliation":[{"name":"University clinic of hematology, Faculty of Medicine , Ss. Cyril and Methodius University in Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlate","family":"Stojanoski","sequence":"additional","affiliation":[{"name":"University clinic of hematology, Faculty of Medicine , Ss. Cyril and Methodius University in Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Pivkova-Veljanovska","sequence":"additional","affiliation":[{"name":"University clinic of hematology, Faculty of Medicine , Ss. Cyril and Methodius University in Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Panovska-Stavridis","sequence":"additional","affiliation":[{"name":"University clinic of hematology, Faculty of Medicine , Ss. Cyril and Methodius University in Skopje , RN Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"2026071211414410012_j_prilozi-2023-0047_ref_001","doi-asserted-by":"crossref","unstructured":"Hermouet S, Bigot-Corbel E, Gardie B. Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. Mediators of Inflammation. 2015; 2015:145293.","DOI":"10.1155\/2015\/145293"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_002","doi-asserted-by":"crossref","unstructured":"Pizzi M, Croci GA, Ruggeri M et al. The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases. Cancers (Basel). 2021 Nov 12; 13(22):5666.","DOI":"10.3390\/cancers13225666"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_003","doi-asserted-by":"crossref","unstructured":"Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders. Leukemia. 2008 May; 22(5):905-14.","DOI":"10.1038\/leu.2008.72"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_004","doi-asserted-by":"crossref","unstructured":"Kiladjian JJ, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016 Apr; 30(4):776-81.","DOI":"10.1038\/leu.2015.326"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_005","doi-asserted-by":"crossref","unstructured":"Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V et al. Hydroxyurea-related toxicity in 3,411 patients with Ph\u2019-negative MPN. Am J Hematol. 2012 May; 87(5):552-4.","DOI":"10.1002\/ajh.23160"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_006","doi-asserted-by":"crossref","unstructured":"Kerdoud O, Aloua R, Kaouani A, Belem O, Slimani F. Squamous cell carcinoma during long term hydroxyurea treatment: A case report. Int J Surg Case Rep. 2021 Aug; 85:106160.","DOI":"10.1016\/j.ijscr.2021.106160"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_007","doi-asserted-by":"crossref","unstructured":"Hultdin M, Sundstr\u00f6m G, Wahlin A, Lundstr\u00f6m B, Samuelsson J, Birgeg\u00e5rd G, Engstr\u00f6m-Laurent A. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Med Oncol. 2007; 24(1):63-70.","DOI":"10.1007\/BF02685904"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_008","doi-asserted-by":"crossref","unstructured":"Bieniaszewska M, Sobieralski P, Leszczy\u0144ska A, Dutka M. Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population. Leuk Res. 2022 Dec; 123:106962.","DOI":"10.1016\/j.leukres.2022.106962"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_009","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M et al; PROUD-PV Study Group. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020 Mar; 7(3):e196-e208. Epub 2020 Jan 31. Erratum in: Lancet Haematol. 2020 Feb 25;"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_010","doi-asserted-by":"crossref","unstructured":"Okikiolu J, Woodley C, Cadman-Davies L, O\u2019Sullivan J, Radia D, Garcia NC et al. Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys). Leuk Res Rep. 2022 Dec 16; 19:100360.","DOI":"10.1016\/j.lrr.2022.100360"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_011","doi-asserted-by":"crossref","unstructured":"Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P et al. Benefits and pitfalls of pegylated interferon-\u03b12a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica. 2018 Mar; 103(3):438-446.","DOI":"10.3324\/haematol.2017.181297"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_012","doi-asserted-by":"crossref","unstructured":"Gowin K, Jain T, Kosiorek H, Tibes R, Camoriano J, Palmer J, Mesa R. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leuk Res. 2017 Mar; 54:73-77.","DOI":"10.1016\/j.leukres.2017.01.006"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_013","doi-asserted-by":"crossref","unstructured":"Qin A, Urbanski RW, Yu L, Ahmed T, Mascarenhas J. An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future. Front Oncol. 2023 Jan 19; 13:1109866.","DOI":"10.3389\/fonc.2023.1109866"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_014","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Komatsu N, Gill H, Jin J,Lee SE, Hou HA et al. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022 Sep; 18(27):2999-3009.","DOI":"10.2217\/fon-2022-0596"},{"key":"2026071211414410012_j_prilozi-2023-0047_ref_015","doi-asserted-by":"crossref","unstructured":"Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr; 4(4):e165-e175. Epub 2017 Mar 11. Erratum in: Lancet Haematol. 2017 Jun; 4(6):e257.","DOI":"10.1016\/S2352-3026(17)30030-3"}],"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2023-0047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:34:46Z","timestamp":1783899286000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2023-0047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,12,18]]},"published-print":{"date-parts":[[2023,12,1]]}},"alternative-id":["10.2478\/prilozi-2023-0047"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2023-0047","relation":{},"ISSN":["1857-8985"],"issn-type":[{"value":"1857-8985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}